DOCSLIB.ORG

Dose Adjusted R-EPOCH Information for Patients and Caregivers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dose Adjusted R-EPOCH Information for Patients and Caregivers Dose Adjusted R-EPOCH Information for Patients and Caregivers This is a chemotherapy regimen that your doctor prescribed for the treatment of your cancer. R-EPOCH includes: • Rituximab (Rituxan®) • Etoposide (VP-16, Toposar®) • Prednisone • Vincristine (Oncovin®) • Cyclophosphamide (Cytoxan®) • Doxorubicin (Adriamycin®, H-Daunorubicin) How is this regimen given? • Cycle 1 is administered in the inpatient (hospital) setting. Subsequent cycles can be administered in the outpatient (infusion) setting. Day 1: • Rituximab will be administered by intravenous (IV) infusion on Day 1. o The infusion rate depends upon whether this is your first infusion, second infusion or subsequent infusion(s), and how well you tolerated the infusion previously. Therefore, infusion durations may vary. o Occasionally, the Rituximab dose may be split over several days, moved to a different day or omitted completely. Days 1-4: • Etoposide, Vincristine and Doxorubicin will be administered by IV as a continuous infusion over 24 hours on Days 1–4. In the outpatient setting, there will be daily infusion bag hook-ups, changes or disconnects on Days 1, 2, 3, 4 and 5. Department of Pharmacy Services -1- Days 1-5: • Prednisone is taken by mouth every 12 hours on Days 1–5. Day 5: • Cyclophosphamide will be administered by IV infusion over 30 minutes on Day 5. IV fluids may also be administered on treatment days. This chemotherapy regimen is typically repeated every 21 days. Are there other medications I will receive with this regimen? Yes. You will receive other medications to help prevent possible side effects of the chemotherapy or to help the chemotherapy work better. Medications will be given to: • Prevent nausea before you receive your chemotherapy. o Ondansetron (Zofran®) • Treat nausea as needed during your treatment. These medications work best if taken as soon as you notice any nausea. o Prochlorperazine (Compazine®), Lorazepam (Ativan®) • Prevent allergic reactions during your infusion(s) before your treatment. o Acetaminophen (Tylenol®) and Diphenhydramine (Benadryl®) will be given before administration of Rituximab. • Treat an allergic reaction during your treatment. o Acetaminophen (Tylenol®), Diphenhydramine (Benadryl®), Meperidine (Demerol®) • Support your immune system after your treatment. o Filgrastim (Neupogen® or similar) is given as a Subcutaneous subcutaneous injection beginning the first day after Injection: A shot treatment. given into the fat layer between Pegfilgrastim (Neulasta® or similar) is given as a o the skin and subcutaneous injection or applied as a patch on the muscle. skin once per cycle. Department of Pharmacy Services Dose-Adjusted R-EPOCH Information for Patients and Caregivers - 2 - • Prevent viral infections (prescribed) • Prevent bacterial infections (prescribed) • Prevent and treat nausea (prescribed for home use) What side effects can occur with this regimen? This information does not cover all possible side effects. The side effects experienced most frequently are included, especially when these medications are given in combination. You know what is normal for your body. If you are experiencing symptoms not listed here, please contact your clinic with questions. Fertility concerns Cancer treatment may affect your fertility. Discuss any concerns with your doctor before beginning treatment. Side Effects During Infusion Side effects What can I do? When to call the clinic: Infusion Reaction — a Alert your nurse reaction that can occur immediately if you during or following experience any of the infusion of the drug. following during your The reactions may infusion: include: • Shortness of breath • Low blood pressure • Chills • Tightness in chest • Flushing of • Burning in stomach face/chest and/or back • Sweating • Difficulty breathing • Rash • Face/throat swelling • Itching or dizziness Department of Pharmacy Services Dose-Adjusted R-EPOCH Information for Patients and Caregivers - 3 - Hypotension — low • Maintain proper • Dizziness blood pressure. hydration and • Lightheadedness nutrition. • Fainting • Unable to eat or drink Infusion site Alert your nurse extravasation — immediately if you Leaking of the anti- experience any: cancer drug from a • Irritation around IV blood vessel into site including surrounding tissue blistering causing pain and/or • Pain tissue damage. Side Effects at Home Side effects What can I do? When to call the clinic: Decreased blood cell • The clinic will monitor • Temperature of counts — low red blood your labs so follow 100.5˚F or higher – cells and white blood your instructions contact the clinic cells can weaken the regarding your blood immediately. immune system. Low draw schedule. • Any signs of infection platelets can cause • Wash hands or use (fever, cough, etc.) bruising and prevent alcohol–based • Unusual tiredness or blood from clotting. sanitizers regularly. weakness. • Avoid close contact • Shortness of breath or Beginning the with others who are difficulty breathing. second week of sick. • Unusual bleeding or each cycle, labs • Avoid activities with bruising. are required high risk for injury or • Dizziness. twice a week. bleeding such as • Lightheadedness. contact sports. • Rest when tired; stand up slowly. Department of Pharmacy Services Dose-Adjusted R-EPOCH Information for Patients and Caregivers - 4 - Side effects What can I do? When to call the clinic: Fatigue/Tiredness • Do not over-exert • Unable to perform yourself. normal daily activities. • Rest when you are tired. • Ask for help. • Eat and drink well. Increased risk of • Wash hands or use • Temperature of infection alcohol–based 100.5˚F or higher – sanitizers regularly. contact the clinic • Avoid close contact immediately. with others who are • Chills sick. • Cough • Follow your doctor’s • Sore throat instructions regarding • Ear pain your blood draw • Sinus pain schedule. • Sore neck • Skin rash • Sores or white coating in mouth • Pain when urinating • Swelling or redness anywhere • Shortness of breath • Difficulty breathing Nausea/Vomiting • Stay well-hydrated. • Unable to stay • Use the anti-nausea hydrated or unable to medication prescribed keep fluids down (not by the clinic. able to drink 8–10 cups of liquid per day) • Eat smaller, more — contact the clinic frequent immediately. meals/snacks. Department of Pharmacy Services Dose-Adjusted R-EPOCH Information for Patients and Caregivers - 5 - Side effects What can I do? When to call the clinic: • Avoid an empty • The anti-nausea stomach. medication is not • Eat bland foods. working. Tumor lysis syndrome • Drink lots of fluids. • Decrease in amount or number of times you — a condition that can • Urinate often. occur after treatment. urinate. • Take preventive As tumor cells die, they medications as break apart and release prescribed by your their contents into the doctor. blood. This may cause (Ex. Allopurinol) damage to organs including the kidneys, heart and liver. The greatest risk of developing this syndrome is following Cycle 1. Alopecia — hair loss. Use head coverings to Ask the clinic for a protect against sun and prescription if you plan cold temperatures. to purchase a wig. (Check with your insurance company to see if this is a covered expense.) Mucositis — irritation • Brush gently using a • Unable to stay of the lining of the soft toothbrush. hydrated (not able to digestive system most • Rinse 3–4 times daily drink 8–10 cups of often seen as sores in with a solution of liquid per day) — the mouth, throat or ¼ tsp baking soda + Contact the clinic lips. 1/8 tsp salt in 1 cup immediately. warm water. • Pain not controlled by • Use pain medications medications. as prescribed. • Unable to eat. Department of Pharmacy Services Dose-Adjusted R-EPOCH Information for Patients and Caregivers - 6 - Side effects What can I do? When to call the clinic: Hemorrhagic cystitis — • Stay hydrated. Drink • You notice blood in when the lining of the up to 2 liters per day your urine (orange or bladder becomes of fluid. pink/red tinged). inflamed and starts to • Urinate frequently. bleed. Blood is seen in the urine. Cardiac dysfunction — • You may have tests to • Shortness of breath or inability of the heart assess your heart difficulty breathing, muscle to adequately function during especially when laying pump blood to supply treatment. down. oxygen to the body. • Rapid swelling of your legs. • Chest pain. • Feeling like you have an irregular heartbeat. Change in urine color • Do not be alarmed if to Red/Orange your urine, sweat, saliva or tears are red/orange colored. • This color change may occur for a few days. Constipation • Stay well-hydrated. • No bowel movement in • Eat at regular times 2–3 or more days. each day. • Abdominal pain, nausea, vomiting. • Include high fiber and “bulky” foods. • Be as active as possible. • Review constipation handouts. Department of Pharmacy Services Dose-Adjusted R-EPOCH Information for Patients and Caregivers - 7 - Side effects What can I do? When to call the clinic: Peripheral Neuropathy • Notify the clinic at Discomfort that affects numbness, tingling, your next visit, as this your ability to work or burning or weakness in can worsen with perform normal the hands/fingers, additional treatments. activities such as: feet/toes, legs. • Unable to grasp a pen/pencil. • Unable to button your shirt. • Unable to feel the bottoms of your feet, making walking difficult. Anorexia • Stay well-hydrated. • Unable to stay loss of appetite. • Eat smaller, more hydrated — contact frequent meals/ the clinic immediately. snacks that are high in •
Load more

Recommended publications
  • Primary Effusion Lymphoma Without an Effusion: a Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient
    Hindawi Case Reports in Hematology Volume 2018, Article ID 9368451, 5 pages https://doi.org/10.1155/2018/9368451 Case Report Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient Hamza Hashmi ,1 Drew Murray,1 Samer Al-Quran ,2 and William Tse3 1Division of Hematology and Oncology, University of Louisville, Louisville, KY, USA 2Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA 3Division of Blood and Marrow Transplant, University of Louisville, Louisville, KY, USA Correspondence should be addressed to Hamza Hashmi; [email protected] Received 26 August 2017; Revised 5 December 2017; Accepted 27 December 2017; Published 28 January 2018 Academic Editor: Tatsuharu Ohno Copyright © 2018 Hamza Hashmi et al. )is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Primary effusion lymphoma (PEL) is a unique form of non-Hodgkin lymphoma, usually seen in severely immunocompromised, HIV-positive patients. PEL is related to human herpesvirus-8 (HHV-8) infection, and it usually presents as a lymphomatous body cavity effusion in the absence of a solid tumor mass. )ere have been very few case reports of HIV-positive patients with HHV-8- positive solid tissue lymphomas not associated with an effusion (a solid variant of PEL). In the absence of effusion, establishing an accurate diagnosis can be challenging, and a careful review of morphology, immunophenotype, and presence of HHV-8 is necessary to differentiate from other subtypes of non-Hodgkin lymphoma.
    [Show full text]
  • BC Cancer Protocol Summary for Treatment of Lymphoma with Dose- Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide
    BC Cancer Protocol Summary for Treatment of Lymphoma with Dose- Adjusted Etoposide, DOXOrubicin, vinCRIStine, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate Protocol Code LYEPOCHR Tumour Group Lymphoma Contact Physician Dr. Laurie Sehn Dr. Kerry Savage ELIGIBILITY: One of the following lymphomas: . Patients with an aggressive B-cell lymphoma and the presence of a dual translocation of MYC and BCL2 (i.e., double-hit lymphoma). Histologies may include DLBCL, transformed lymphoma, unclassifiable lymphoma, and intermediate grade lymphoma, not otherwise specified (NOS). Patients with Burkitt lymphoma, who are not candidates for CODOXM/IVACR (such as those over the age of 65 years, or with significant co-morbidities) . Primary mediastinal B-cell lymphoma Ensure patient has central line EXCLUSIONS: . Cardiac dysfunction that would preclude the use of an anthracycline. TESTS: . Baseline (required before first treatment): CBC and diff, platelets, BUN, creatinine, bilirubin. ALT, LDH, uric acid . Baseline (required, but results do not have to be available to proceed with first treatment): results must be checked before proceeding with cycle 2): HBsAg, HBcoreAb, . Baseline (optional, results do not have to be available to proceed with first treatment): HCAb, HIV . Day 1 of each cycle: CBC and diff, platelets, (and serum bilirubin if elevated at baseline; serum bilirubin does not need to be requested before each treatment, after it has returned to normal), urinalysis for microscopic hematuria (optional) . Days 2 and 5 of each cycle (or days of intrathecal treatment): CBC and diff, platelets, PTT, INR . For patients on cyclophosphamide doses greater than 2000 mg: Daily urine dipstick for blood starting on day cyclophosphamide is given.
    [Show full text]
  • Low-Cost Epoch-Based Correlation Prefetching for Commercial Applications Yuan Chou Architecture Technology Group Microelectronics Division
    Low-Cost Epoch-Based Correlation Prefetching for Commercial Applications Yuan Chou Architecture Technology Group Microelectronics Division 1 Motivation Performance of many commercial applications limited by processor stalls due to off-chip cache misses Applications characterized by irregular control-flow and complex data access patterns Software prefetching and simple stride-based hardware prefetching ineffective Hardware correlation prefetching more promising - can remember complex recurring data access patterns Current correlation prefetchers have severe drawbacks but we think we can overcome them 2 Talk Outline Traditional Correlation Prefetching Epoch-Based Correlation Prefetching Experimental Results Summary 3 Traditional Correlation Prefetching Basic idea: use current miss address M to predict N future miss addresses F ...F (where N = prefetch depth) 1 N Miss address sequence: A B C D E F G H I assume N=2 Use A to prefetch B C Use D to prefetch E F Use G to prefetch H I Correlations recorded in correlation table Correlation table size proportional to application working set 4 Correlation Prefetching Drawbacks Very large correlation tables needed for commercial apps - impractical to store on-chip No attempt to eliminate all naturally overlapped misses Miss address sequence: A B C D E F G H I time A C F H B D G I E compute off-chip access 5 Correlation Prefetching Drawbacks Very large correlation tables needed for commercial apps - impractical to store on-chip No attempt to eliminate all naturally overlapped misses Miss address sequence:
    [Show full text]
  • The Geologic Time Scale Is the Eon
    Exploring Geologic Time Poster Illustrated Teacher's Guide #35-1145 Paper #35-1146 Laminated Background Geologic Time Scale Basics The history of the Earth covers a vast expanse of time, so scientists divide it into smaller sections that are associ- ated with particular events that have occurred in the past.The approximate time range of each time span is shown on the poster.The largest time span of the geologic time scale is the eon. It is an indefinitely long period of time that contains at least two eras. Geologic time is divided into two eons.The more ancient eon is called the Precambrian, and the more recent is the Phanerozoic. Each eon is subdivided into smaller spans called eras.The Precambrian eon is divided from most ancient into the Hadean era, Archean era, and Proterozoic era. See Figure 1. Precambrian Eon Proterozoic Era 2500 - 550 million years ago Archaean Era 3800 - 2500 million years ago Hadean Era 4600 - 3800 million years ago Figure 1. Eras of the Precambrian Eon Single-celled and simple multicelled organisms first developed during the Precambrian eon. There are many fos- sils from this time because the sea-dwelling creatures were trapped in sediments and preserved. The Phanerozoic eon is subdivided into three eras – the Paleozoic era, Mesozoic era, and Cenozoic era. An era is often divided into several smaller time spans called periods. For example, the Paleozoic era is divided into the Cambrian, Ordovician, Silurian, Devonian, Carboniferous,and Permian periods. Paleozoic Era Permian Period 300 - 250 million years ago Carboniferous Period 350 - 300 million years ago Devonian Period 400 - 350 million years ago Silurian Period 450 - 400 million years ago Ordovician Period 500 - 450 million years ago Cambrian Period 550 - 500 million years ago Figure 2.
    [Show full text]
  • Late Neogene Chronology: New Perspectives in High-Resolution Stratigraphy
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Columbia University Academic Commons Late Neogene chronology: New perspectives in high-resolution stratigraphy W. A. Berggren Department of Geology and Geophysics, Woods Hole Oceanographic Institution, Woods Hole, Massachusetts 02543 F. J. Hilgen Institute of Earth Sciences, Utrecht University, Budapestlaan 4, 3584 CD Utrecht, The Netherlands C. G. Langereis } D. V. Kent Lamont-Doherty Earth Observatory of Columbia University, Palisades, New York 10964 J. D. Obradovich Isotope Geology Branch, U.S. Geological Survey, Denver, Colorado 80225 Isabella Raffi Facolta di Scienze MM.FF.NN, Universita ‘‘G. D’Annunzio’’, ‘‘Chieti’’, Italy M. E. Raymo Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 N. J. Shackleton Godwin Laboratory of Quaternary Research, Free School Lane, Cambridge University, Cambridge CB2 3RS, United Kingdom ABSTRACT (Calabria, Italy), is located near the top of working group with the task of investigat- the Olduvai (C2n) Magnetic Polarity Sub- ing and resolving the age disagreements in We present an integrated geochronology chronozone with an estimated age of 1.81 the then-nascent late Neogene chronologic for late Neogene time (Pliocene, Pleisto- Ma. The 13 calcareous nannoplankton schemes being developed by means of as- cene, and Holocene Epochs) based on an and 48 planktonic foraminiferal datum tronomical/climatic proxies (Hilgen, 1987; analysis of data from stable isotopes, mag- events for the Pliocene, and 12 calcareous Hilgen and Langereis, 1988, 1989; Shackle- netostratigraphy, radiochronology, and cal- nannoplankton and 10 planktonic foram- ton et al., 1990) and the classical radiometric careous plankton biostratigraphy.
    [Show full text]
  • Advances in Llm
    LLM ADVANCES IN LLM Current Developments in the Management of Leukemia, Lymphoma, and Myeloma Section Editor: Susan O’Brien, MD Prophylaxis of Central Nervous System Relapse in Patients With Lymphoma Avyakta Kallam, MD Assistant Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center Omaha, Nebraska H&O How common is central nervous system AK Patients can be asymptomatic at the time of diag- relapse in lymphoma? nosis. When symptoms do occur, they can be subtle, and include nonspecific headaches, blurred vision, and AK The incidence of central nervous system (CNS) mild confusion. Overt symptoms include cranial nerve relapse in lymphoma depends on the type of disease. In palsies and focal neurologic deficits, such as weakness more-aggressive, high-grade lymphomas, such as Burkitt and imbalance. lymphoma and lymphoblastic lymphoma, the rate of Imaging studies, such as magnetic resonance imaging CNS relapse can reach 30% to 50%. In diffuse large of the brain, can help detect the presence of CNS involve- B-cell lymphoma, CNS involvement occurs in approxi- ment. The diagnostic test of choice, however, is lumbar mately 2% to 5% of patients. puncture with flow cytometry of the cerebral spinal fluid. H&O What are the risk factors? H&O Does CNS relapse impact prognosis? AK The validated Central Nervous System–International AK CNS relapse confers a poor prognosis in patients with Prognostic Index (CNS-IPI) scoring system is used to lymphoma, particularly diffuse large B-cell lymphoma. identify patients who are at high risk for CNS relapse. The median overall survival in a patient who develops The scoring system takes into account 6 characteristics: CNS relapse is approximately 3 to 4 months.
    [Show full text]
  • Part 2A of Form ADV Firm Brochure
    Item 1: Cover Page Part 2A of Form ADV Firm Brochure 399 Park Avenue New York, NY 10022 www.eipny.com January 27, 2021 This brochure provides information about the qualifications and business practices of Epoch Investment Partners, Inc. (“Epoch” or the “Firm”). If you have any questions about the contents of this brochure, please contact David A. Barnett, Epoch’s Managing Attorney and Chief Compliance Officer at 399 Park Avenue, New York, NY 10022 or call (212) 303-7200. The information in this brochure has not been approved or verified by the United States Securities and Exchange Commission (“SEC”) or by any state securities authority. In addition, registration with the SEC as an investment adviser does not imply a certain level of skill or training. Additional information about Epoch is also available on the SEC’s website at: www.adviserinfo.sec.gov. Epoch Investment Partners Part 2A of Form ADV Item 2: Material Changes Our last annual update was dated January 27, 2020. Since the last annual update, there have been no material changes to our Form ADV Part 2A. To the extent that we materially amend our Brochure in the future, you will receive either an amended Brochure or a summary of any material changes to the annual update within 120 days of the close of our fiscal year or earlier if required. We may also provide you with an interim amended Brochure based on material changes or new information. ___________________________________________________________________________ 2 Epoch Investment Partners Part 2A of Form ADV Item 3: Table of Contents Item 2: Material Changes ..............................................................................................................
    [Show full text]
  • Extracavitary/Solid Variant of Primary Effusion Lymphoma Yoonjung Kim, Mda,1, Vasiliki Leventaki, Mda, Feriyl Bhaijee, Mbchbb, ⁎ Courtney C
    Available online at www.sciencedirect.com Annals of Diagnostic Pathology 16 (2012) 441–446 Extracavitary/solid variant of primary effusion lymphoma Yoonjung Kim, MDa,1, Vasiliki Leventaki, MDa, Feriyl Bhaijee, MBChBb, ⁎ Courtney C. Jackson, MDb, L. Jeffrey Medeiros, MDa, Francisco Vega, MD PhDa, aDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA bDepartment of Pathology, University of Mississippi Medical Center, Jackson, MS, USA Abstract Primary effusion lymphoma (PEL) is a distinct clinicopathologic entity associated with human herpesvirus 8 (HHV8) infection that mostly affects patients with immunodeficiency. Primary effusion lymphoma usually presents as a malignant effusion involving the pleural, peritoneal, and/or pericardial cavities without a tumor mass. Rare cases of HHV8-positive lymphoma with features similar to PEL can present as tumor masses in the absence of cavity effusions and are considered to represent an extracavitary or solid variant of PEL. Here, we report 3 cases of extracavitary PEL arising in human immunodeficiency virus–infected men. Two patients had lymphadenopathy and underwent lymph node biopsy. One patient had a mass involving the ileum and ascending colon. In lymph nodes, the tumor was predominantly sinusoidal. The tumor involving the ileum and ascending colon presented as 2 masses, 12.5 × 10.6 × 2.6 cm in the colon and 3.6 × 2.7 × 1.9 cm in the ileum. In each case, the neoplasms were composed of large anaplastic cells, and 2 cases had “hallmark cells.” Immunohistochemistry showed that all cases were positive for HHV8 and CD138. One case also expressed CD4 and CD30, and 1 case was positive for Epstein-Barr virus–encoded RNA.
    [Show full text]
  • Formal Ratification of the Subdivision of the Holocene Series/ Epoch
    Article 1 by Mike Walker1*, Martin J. Head 2, Max Berkelhammer3, Svante Björck4, Hai Cheng5, Les Cwynar6, David Fisher7, Vasilios Gkinis8, Antony Long9, John Lowe10, Rewi Newnham11, Sune Olander Rasmussen8, and Harvey Weiss12 Formal ratification of the subdivision of the Holocene Series/ Epoch (Quaternary System/Period): two new Global Boundary Stratotype Sections and Points (GSSPs) and three new stages/ subseries 1 School of Archaeology, History and Anthropology, Trinity Saint David, University of Wales, Lampeter, Wales SA48 7EJ, UK; Department of Geography and Earth Sciences, Aberystwyth University, Aberystwyth, Wales SY23 3DB, UK; *Corresponding author, E-mail: [email protected] 2 Department of Earth Sciences, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, Ontario LS2 3A1, Canada 3 Department of Earth and Environmental Sciences, University of Illinois, Chicago, Illinois 60607, USA 4 GeoBiosphere Science Centre, Quaternary Sciences, Lund University, Sölveg 12, SE-22362, Lund, Sweden 5 Institute of Global Change, Xi’an Jiaotong University, Xian, Shaanxi 710049, China; Department of Earth Sciences, University of Minne- sota, Minneapolis, MN 55455, USA 6 Department of Biology, University of New Brunswick, Fredericton, New Brunswick E3B 5A3, Canada 7 Department of Earth Sciences, University of Ottawa, Ottawa K1N 615, Canada 8 Centre for Ice and Climate, The Niels Bohr Institute, University of Copenhagen, Julian Maries Vej 30, DK-2100, Copenhagen, Denmark 9 Department of Geography, Durham University, Durham DH1 3LE, UK 10
    [Show full text]
  • Dose-Adjusted Epoch and Rituximab for the Treatment of Double
    Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome by Anna Dodero, Anna Guidetti, Fabrizio Marino, Alessandra Tucci, Francesco Barretta, Alessandro Re, Monica Balzarotti, Cristiana Carniti, Chiara Monfrini, Annalisa Chiappella, Antonello Cabras, Fabio Facchetti, Martina Pennisi, Daoud Rahal, Valentina Monti, Liliana Devizzi, Rosalba Miceli, Federica Cocito, Lucia Farina, Francesca Ricci, Giuseppe Rossi, Carmelo Carlo-Stella, and Paolo Corradini Haematologica. 2021; Jul 22. doi: 10.3324/haematol.2021.278638 [Epub ahead of print] Received: February 26, 2021. Accepted: July 13, 2021. Citation: Anna Dodero, Anna Guidetti, Fabrizio Marino, Alessandra Tucci, Francesco Barretta, Alessandro Re, Monica Balzarotti, Cristiana Carniti, Chiara Monfrini, Annalisa Chiappella, Antonello Cabras, Fabio Facchetti, Martina Pennisi, Daoud Rahal, Valentina Monti, Liliana Devizzi, Rosalba Miceli, Federica Cocito, Lucia Farina, Francesca Ricci, Giuseppe Rossi, Carmelo Carlo-Stella, and Paolo Corradini. Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit d fuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.
    [Show full text]
  • Mainstay Epoch U.S. Small Cap Fund a Quality U.S
    Q2 - 2017 All data as of 6/30/17 A*: MOPAX | INV: MOINX | C: MOPCX | I: MOPIX | R1: MOPRX | R2: MOTRX | R3: MOVRX MainStay Epoch U.S. Small Cap Fund A quality U.S. small cap fund Seeks: Long -term capital appreciation by investing primarily in securities of small -cap companies. Morningstar Category: Small Blend Benchmark: Russell 2500 Index Focus on cash flow Active management Risk management helps lower volatility The Subadvisor invests in companies with a history of The team invests in U.S. small -cap companies they The team employs a comprehensive risk generating free cash flow, and management teams fully understand, that meet strict free cash flow management discipline designed to limit security committed to using that cash to increase shareholder criteria, and that can be bought at an attractive price. and portfolio level risk. value. 1,2 3 Average Annual Total Returns (%) SI = Since Inception Fund Statistics Fund Inception 1/12/87 QTR YTD 1 Yr 3 Yrs 5 Yrs 10 Yrs SI Total Net Assets (all classes) $587.1 million Class A (NAV) 1.57 6.09 18.65 6.27 13.00 5.68 9.82 Distribution Frequency Annually (max. 5.5% load) -4.02 0.25 12.13 4.29 11.73 5.08 9.62 Number of Holdings 80 Investor Class (NAV) 1.52 5.95 18.32 5.99 12.69 5.44 9.74 Annual Turnover Rate (%) 65 (max. 5.5% load) -4.06 0.12 11.82 4.01 11.42 4.85 9.54 Class I (no load) 1.63 6.21 18.92 6.53 13.29 6.00 10.15 Fund Benchmark Russell 2500 Index 2.13 5.97 19.84 6.93 14.04 7.42 — Weighted Avg.
    [Show full text]
  • EPOCH T&C® Server™
    EPOCH T&C® Server™ Real-Time Telemetry and Command Processing EPOCH Integrated Product Suite Overview Features ® EPOCH T&C Server™ provides complete off-the-shelf satellite telemetry and • Incorporates KISI’s experience supporting command processing for operations and test environments. EPOCH T&C Server more than 298 satellite missions provides front- end data processing, distribution, and command formatting as part • Eliminates risk and cost associated with of the Kratos Integral Systems International (Kratos ISI)end-to-end database driven custom development command and control solution, EPOCH IPS™ (Integrated Product Suite). • Enables operators to fly a single satellite or a constellation using the same software Under operator control from the EPOCH Client™, EPOCH T&C Server can manage a single satellite, multiple satellites from different manufacturers, or an entire • Supports any satellite command and constellation of satellites. The EPOCH T&C Server supports LEO, GEO, and Deep telemetry format from any manufacturer Space missions, and provides out-of-the-box compatibility for most commercial • Supports growth through distributed satellite designs of the last 17 years, including: design, so you can add satellites easily • Provides high-level status rollups from • Airbus Eurostar 2000, 2000+, 3000, LeoStar • Lockheed Martin 7000, A2100 multiple satellites and complex ground • Loral FS/LS-1300 • Mitsubishi Electric DS2000 segments • Thales Spacebus 3000, 4000 • Orbital ATK GEOStar • Provides the flexibility to perform any • Boeing 376, 601/601HP, 702 (HP, MP, function from anywhere on a network SP, GEM) • Offers redundancy by running multiple copies of the software for high reliability In addition to commercial satellite support, EPOCH T&C Server Supports unique • Runs on UNIX and Linux servers military and science platforms from Astrium, Applied Physics Laboratory, Lockheed • Includes an API for integration with third- Martin, Northrop Grumman, and OHB to name a few.
    [Show full text]